Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common antibiotic ease Kids' bowel disease?

NCT ID NCT07646223

Disease control Sponsor: Tampere University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 11, 2026 · Updated 3 times

Summary

This study tests whether oral vancomycin, an antibiotic, can help children aged 6-15 with inflammatory bowel disease (IBD), especially types linked to liver problems. About 140 kids will either get vancomycin plus standard care or standard care alone for up to a year. Researchers will check if it improves symptoms, gut bacteria, and overall health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oral vancomycin
What this could lead to
If it works, this could point toward a new treatment option for children with certain types of inflammatory bowel disease, especially those with liver involvement.
What could go wrong
This is an early Phase 2 trial with only 140 children, so results may not apply to everyone. The treatment requires long-term use and may cause side effects or not work for all types of colitis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 15 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria. * children aged 6-15 years * able to swallow capsules * are scheduled for diagnostic endoscopy at Tampere University * has not received oral vancomycin before * do not have active infection (such as clostridium or other bacteria) * has not received new interventions (medications or new conventional therapies) for treating IBD was given within the past 4 weeks before starting OVT. Exclusion Criteria: * The presence of PSC without UC, Crohn's disease type of inflammatory bowel diseases. * Under the age of 6 years old. * Is unable to swallow capsules. * Had a previous allergic reaction to vancomycin (such as vancomycin allergy) and/or other related antibiotics similar to vancomycin. * Presence of malignant disease or potential need for liver transplantation within the following 12 months. * Pregnancy * Known renal insufficiency or chronic renal disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pediatric inflammatory bowel diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cholangitis, Sclerosing colitis inflammatory bowel disease primary sclerosing cholangitis ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pediatric inflammatory bowel diseases Primary sclerosing cholangitis (PSC) Ulcerative colitis (UC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tampere University Hospital

    Tampere, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.